VRNA241220C20000
- 22.20
- +0.09+0.41%
Verona Pharma Newsroom
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Jefferies Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $50
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Verona Pharma Is Maintained at Buy by Canaccord Genuity
A Quick Look at Today's Ratings for Verona Pharma(VRNA.US), With a Forecast Between $42 to $64
Verona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth Prospects
BTIG Remains a Buy on Verona Pharma (VRNA)
Verona Pharma Is Maintained at Buy by Truist Securities
Verona Pharma Analyst Ratings
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $38
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Verona Pharma (VRNA) and Hims & Hers Health (HIMS)
Piper Sandler Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Piper Sandler Remains a Buy on Verona Pharma (VRNA)
Wells Fargo Initiates Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $50
Wells Fargo Initiates Verona Pharma at Overweight With $50 Price Target
H.C. Wainwright Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Verona Pharma Analyst Ratings
H.C. Wainwright Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36
Buy Rating Affirmed for Verona Pharma Amid Strategic Partnership and Market Potential for Novel COPD Treatment
H.C. Wainwright Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $36